AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21921285 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy with tamoxifen
Number of subjects: 431
Study 18300336 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 39
Study 18300336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 39
Study 18300336 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 (Quality of Life Measure)
Number of subjects: 39
Study 18300336 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 39
Study 18300336 — intervention group
Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 39
Study 17245184 — intervention group
Group type: EXPERIMENTAL
Intervention: I methylene blue (100, 200, 300, 400, 500, or 1000 microCi)
Number of subjects: 12
Study 17245184 — intervention group
Group type: EXPERIMENTAL
Intervention: I methylene blue (200 microCi)
Number of subjects: 12
Study 17245184 — intervention group
Group type: EXPERIMENTAL
Intervention: I methylene blue (various doses)
Number of subjects: 12
Study 17245184 — intervention group
Group type: EXPERIMENTAL
Intervention: I methylene blue (1 mCi)
Number of subjects: 12
Study 14602191 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC K4MP
Number of subjects: 10
Study 14602191 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC K100LVP
Number of subjects: 10
Study 10718159 — intervention group
Group type: EXPERIMENTAL
Intervention: High environmental risk group (N = 92)
Number of subjects: 198
Study 10718159 — intervention group
Group type: COMPARATOR
Intervention: Low environmental risk group (N = 106)
Number of subjects: 198
Study 8634210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 18
Study 8634210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine
Number of subjects: 18
Study 8634210 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 1430705 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air heating (off1‐on2) from September 9 to 17, then thermostat set to 22 degrees C from 8 PM to 8 AM between September 18 and 25
Number of subjects: 51
Study 1430705 — intervention group
Group type: COMPARATOR
Intervention: Control group (off1‐off2) kept forced air heating off during the entire study period
Number of subjects: 51
Study 3886496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 33
Study 3886496 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Number of subjects: 33
Study 3886496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Ultrasonography and Computed Tomography)
Number of subjects: 33
Study 29992150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Chamaemelum nobile gel
Number of subjects: 55
Study 29992150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 27401569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) monthly for 1 year
Number of subjects: 810
Study 27401569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) once per school term
Number of subjects: 810
Study 27401569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) within the past 30 days
Number of subjects: 810
Study 24562806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus abciximab
Number of subjects: 452
Study 24562806 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 452
Study 24562806 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 452
Study 24562806 — intervention group
Group type: COMPARATOR
Intervention: No aspiration
Number of subjects: 452
Study 24562806 — intervention group
Group type: EXPERIMENTAL
Intervention: maxST residual at 60 min
Number of subjects: 452
Study 24562806 — intervention group
Group type: EXPERIMENTAL
Intervention: Qwave at 60 min
Number of subjects: 452
Study 24562806 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (MVO)
Number of subjects: 452
Study 23017003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% sodium hypochlorite rinse
Number of subjects: 40
Study 23017003 — intervention group
Group type: COMPARATOR
Intervention: Distilled water rinse (Control)
Number of subjects: 40
Study 20658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume resistance exercise (EX; n = 12) performed every other day at 80% of maximal for 14 days
Number of subjects: 17
Study 20658567 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 5) with no exercise
Number of subjects: 17
Study 20658567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume resistance exercise (EX; n = 12)
Number of subjects: 17
Study 20658567 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 5)
Number of subjects: 17
Study 17825129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER (300 mg once daily for patients ≥ 75 years; 300-400 mg once daily for patients < 75 years)
Number of subjects: 919
Study 17825129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER (open-label treatment after placebo-controlled studies)
Number of subjects: 919
Study 15950149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (LD)
Number of subjects: 41
Study 15950149 — intervention group
Group type: COMPARATOR
Intervention: Supine position (SP)
Number of subjects: 41
Study 12898857 — intervention group
Group type: COMPARATOR
Intervention: Branched-chain amino acids (BCAA) concentrations measured by chromatography method with amino acid analyser AAA 400.
Number of subjects: 67
Study 12898857 — intervention group
Group type: COMPARATOR
Intervention: Plasma albumin concentration and urea for KT/V calculation determined by routine methods.
Number of subjects: 67
Study 12898857 — intervention group
Group type: EXPERIMENTAL
Intervention: Total amino acids and branched amino acids measured in study II.
Number of subjects: 67
Study 10598760 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 20% cream
Number of subjects: 116
Study 10598760 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 116
Study 7554782 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (30% energy)
Number of subjects: 16
Study 7554782 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in polyunsaturated fatty acids (30% energy)
Number of subjects: 16
Study 1941057 — intervention group
Group type: COMPARATOR
Intervention: Radiation to the abdomen and mantle (group AX3, 62 patients)
Number of subjects: 226
Study 1941057 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy (group A, 105 patients)
Number of subjects: 226
Study 1941057 — intervention group
Group type: EXPERIMENTAL
Intervention: No further treatment (AC6, 23 patients)
Number of subjects: 226
Study 1941057 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the abdomen and mantle (AX6, 48 patients)
Number of subjects: 226
Study 1941057 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy at 3-month intervals for 1 year (AC10, 26 patients)
Number of subjects: 226
Study 1941057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (MOPP + radiation)
Number of subjects: 226
Study 7174605 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 7174605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27992063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus bendamustine (RB)
Number of subjects: 53
Study 27992063 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus hyperCVAD/MTX/ARAC (RH)
Number of subjects: 53
Study 25340477 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based pulmonary rehabilitation (PR) program
Number of subjects: 42
Study 25340477 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation (PR)
Number of subjects: 42
Study 24664227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 24664227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/d of CoQ10
Number of subjects: 600
Study 24664227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg/d of CoQ10
Number of subjects: 600
Study 21849198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml polidocanol sclerotherapy (30 mg/ml)
Number of subjects: 224
Study 21849198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml polidocanol sclerotherapy (30 mg/ml)
Number of subjects: 224
Study 21849198 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (1 to 4 treatments)
Number of subjects: 224
Study 21849198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml polidocanol sclerotherapy for larger hydroceles/spermatoceles
Number of subjects: 224
Study 21849198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml polidocanol sclerotherapy for larger hydroceles/spermatoceles
Number of subjects: 224
Study 19463396 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 4791
Study 19463396 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended medications at 1 year (including aspirin, clopidogrel, ACE inhibitors, and statins)
Number of subjects: 4791
Study 17462482 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of interstitial cystitis (IC) in males
Number of subjects: 0
Study 17462482 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment of chronic nonbacterial prostatitis (CP)
Number of subjects: 0
Study 15350319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 29
Study 15350319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11452676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 100
Study 11452676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9684851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg twice daily
Number of subjects: 429
Study 9684851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 7873233 — intervention group
Group type: EXPERIMENTAL
Intervention: penicillin + metronidazole
Number of subjects: 40
Study 7873233 — intervention group
Group type: COMPARATOR
Intervention: penicillin
Number of subjects: 40
Study 2896666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate
Number of subjects: 176
Study 2896666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 29955924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Phase I (focused education program and implementation of treatment bundle)
Number of subjects: 1594
Study 29955924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Phase II (provision of resources to implement treatment bundle)
Number of subjects: 1594
Study 29955924 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention
Number of subjects: 1594
Study 29955924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention I
Number of subjects: 1594
Study 29955924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention II
Number of subjects: 1594
Study 27932101 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy of failed graft (Group A)
Number of subjects: 63
Study 27932101 — intervention group
Group type: COMPARATOR
Intervention: Retained failed graft (Group B)
Number of subjects: 63
Study 27932101 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft survival (both groups)
Number of subjects: 63
Study 27932101 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient survival (both groups)
Number of subjects: 63
Study 26431823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rAAV.sFLT-1 (1×10^10 vector genomes)
Number of subjects: 9
Study 26431823 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rAAV.sFLT-1 (1×10^11 vector genomes)
Number of subjects: 9
Study 26431823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gene therapy treatment)
Number of subjects: 9
Study 23259880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incisional local wound infiltration with 1% lidocaine
Number of subjects: 281
Study 23259880 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-incisional local wound infiltration with 1% lidocaine
Number of subjects: 281
Study 23259880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pre- and post-incisional local wound infiltration with 1% lidocaine
Number of subjects: 281
Study 22212257 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric leg extension
Number of subjects: 17
Study 22212257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic leg extension
Number of subjects: 17
Study 22212257 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting muscle tone assessment
Number of subjects: 17
Study 19057117 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA scale measurement for operators with field-dependent cognitive styles
Number of subjects: 0
Study 19057117 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA scale measurement for operators with field-independent cognitive styles
Number of subjects: 0
Study 19057117 — intervention group
Group type: COMPARATOR
Intervention: Control-display pairing tasks for both cognitive styles
Number of subjects: 0
Study 16539087 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-developed consent document
Number of subjects: 1092
Study 16539087 — intervention group
Group type: COMPARATOR
Intervention: Investigator-developed consent document
Number of subjects: 1092
Study 14579214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (0.1 mg)
Number of subjects: 32
Study 14579214 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary nitroglycerin (20 microg)
Number of subjects: 32
Study 11517843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (standard education plus stress-management skills)
Number of subjects: 20
Study 11517843 — intervention group
Group type: COMPARATOR
Intervention: Standard education about risk for breast cancer (control group)
Number of subjects: 20
Study 9625082 — intervention group
Group type: EXPERIMENTAL
Intervention: High leptin concentrations in women with no obese parent
Number of subjects: 49
Study 9625082 — intervention group
Group type: COMPARATOR
Intervention: High leptin concentrations in women with at least one obese parent
Number of subjects: 49
Study 9625082 — intervention group
Group type: COMPARATOR
Intervention: Changes in energy and fat intakes
Number of subjects: 49
Study 7512402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic spiral treatment
Number of subjects: 9
Study 7512402 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 9
Study 7512402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 9
Study 3279023 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day trimipramine
Number of subjects: 34
Study 3279023 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day trimipramine
Number of subjects: 34
Study 30593980 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Number of subjects: 24
Study 30593980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28301619 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP Lotion, 0.05% applied twice daily for 14 days
Number of subjects: 443
Study 28301619 — intervention group
Group type: COMPARATOR
Intervention: VEH (vehicle control)
Number of subjects: 443
Study 26468792 — intervention group
Group type: EXPERIMENTAL
Intervention: Face to face technique
Number of subjects: 21
Study 26468792 — intervention group
Group type: EXPERIMENTAL
Intervention: Back to back technique
Number of subjects: 21
Study 23602678 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed vitrification system
Number of subjects: 75
Study 23602678 — intervention group
Group type: COMPARATOR
Intervention: Open vitrification system
Number of subjects: 75
Study 20731686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg load + 70 mg/hL) administered during donor lung perfusion and peri-operatively to recipients
Number of subjects: 48
Study 20731686 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during donor lung perfusion and peri-operatively to recipients
Number of subjects: 48
Study 20731686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin administration
Number of subjects: 48
Study 19690556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 19690556 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17003096 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment 1 mg/m2.d
Number of subjects: 53
Study 15502685 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective feedback
Number of subjects: 120
Study 15502685 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception training
Number of subjects: 120
Study 15502685 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception training plus feedback
Number of subjects: 120
Study 15502685 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 11102422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily
Number of subjects: 266
Study 11102422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 9181901 — intervention group
Group type: EXPERIMENTAL
Intervention: Urolase fiber (Bard) at 60 Watts for 60 seconds, administered to each lobe at 2, 4, 8 and 10 o'clock positions.
Number of subjects: 100
Study 9181901 — intervention group
Group type: COMPARATOR
Intervention: Fibertom fiber (Dornier) using the 'painting' technique at 3 and 6 months.
Number of subjects: 100
Study 8362533 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 45
Study 8362533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision cholecystectomy
Number of subjects: 45
Study 8362533 — intervention group
Group type: COMPARATOR
Intervention: Kocher's incision cholecystectomy
Number of subjects: 45
Study 31865333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (20-min sessions, 3 days per week for 2 years)
Number of subjects: 132
Study 31865333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 132
Study 30685874 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg daily starting 3 weeks pre-operatively, continued for 1 week after surgical haemostasis)
Number of subjects: 0
Study 30685874 — intervention group
Group type: COMPARATOR
Intervention: IVIG (1 to 2 g/kg administered 1 week pre-operatively, with allowance for a second dose within 1 week after surgical haemostasis)
Number of subjects: 0
Study 30685874 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 30685874 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 0
Study 28233944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylan-Nifedipine-XL
Number of subjects: 20
Study 25957544 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° external rotation brace (ER Group)
Number of subjects: 40
Study 25957544 — intervention group
Group type: COMPARATOR
Intervention: internal rotation sling (IR Group)
Number of subjects: 40
Study 23253363 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory (WM) training program
Number of subjects: 20
Study 23253363 — intervention group
Group type: COMPARATOR
Intervention: Active control group conducting educational activities on memory
Number of subjects: 20
Study 22083055 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 162
Study 22083055 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 162
Study 17909558 — intervention group
Group type: EXPERIMENTAL
Intervention: CESD‐20
Number of subjects: 47
Study 17909558 — intervention group
Group type: EXPERIMENTAL
Intervention: CESD‐10
Number of subjects: 47
Study 17909558 — intervention group
Group type: COMPARATOR
Intervention: Short Form‐36 (SF‐36) subscales
Number of subjects: 47
Study 15956010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (7.5 mg/d for 2 years)
Number of subjects: 95
Study 15956010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 12540786 — intervention group
Group type: COMPARATOR
Intervention: Nadolol plus placebo (N + P)
Number of subjects: 100
Study 12540786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus spironolactone 100 mg/d (N + S)
Number of subjects: 100
Study 12540786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus spironolactone (N + S)
Number of subjects: 100
Study 10803472 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg iv at 150 min) preceded by saline or GHRH at 0 min
Number of subjects: 34
Study 10803472 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH preceded by saline or rhGH (0.005 IU/kg iv at 0 min)
Number of subjects: 34
Study 10803472 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH preceded by rhGH alone or combined with GHRH
Number of subjects: 34
Study 10803472 — intervention group
Group type: EXPERIMENTAL
Intervention: HEX (2 microg/kg iv at 150 min) alone or preceded by rhGH
Number of subjects: 34
Study 8639010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering interventions (active intervention)
Number of subjects: 24968
Study 8639010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24968
Study 8639010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering interventions
Number of subjects: 24968
Study 1705938 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (morphine group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Duramorph (morphine sulphate), 0.5 mg
Number of subjects: 60
Study 1705938 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (Dilaudid group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Dilaudid (hydromorphone hydrochloride), 0.002 mg/kg
Number of subjects: 60
Study 1705938 — intervention group
Group type: COMPARATOR
Intervention: Group I (control group): hyperbaric 1% tetracaine with epinephrine
Number of subjects: 60